Related Experiment Videos
[Ischemic cardiomyopathy: remodeling, hypertrophy, subendocardial risk. Can processes be controlled?]
D Himbert1, A Guiomard, M C Aumont
1Service de cardiologie, hôpital Bichat, Paris.
La Revue Du Praticien
|November 1, 1992
Summary
Ischaemic cardiomyopathy, caused by coronary artery disease, leads to heart failure through ventricular remodelling and hibernating myocardium. Revascularisation and ACE inhibitors can halt its progression and improve prognosis.
Area of Science:
- Cardiology
- Cardiovascular Diseases
- Heart Failure Research
Context:
- Ischaemic cardiomyopathy (ICM) is myocardial dysfunction stemming from coronary artery disease.
- ICM involves segmental infarction causing ventricular remodelling and viable but dysfunctional (hibernating) myocardium.
- This progression often leads to heart failure.
Purpose:
- To outline the pathophysiology of ischaemic cardiomyopathy.
- To discuss therapeutic strategies for arresting the progression of ICM.
- To highlight the role of revascularisation and medical management in improving outcomes.
Summary:
- ICM results from coronary disease, causing myocardial infarction, ventricular remodelling, and myocardial hibernation.
- Therapeutic interventions include myocardial revascularisation (emergency or elective) and limiting ventricular remodelling.
- Angiotensin-converting enzyme (ACE) inhibitors and nitroglycerin are key in managing ventricular remodelling and load.
Impact:
- Revascularisation can halt the adverse progression of ICM.
- Limiting ventricular remodelling through ACE inhibitors and nitroglycerin improves secondary prevention post-infarction.
- The Survival and Ventricular Enlargement (SAVE) study confirmed the benefits of ACE inhibitors in reducing ventricular remodelling and improving prognosis.